NRX Pharmaceuticals (NRXP) EBT Margin (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly EBT Margin came in at 465.36% in Q1 2026, up 3.5% on a QoQ basis from 482.25% in Q4 2025.
NRX Pharmaceuticals (NRXP) EBT Margin (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of EBT Margin data on file, last reported at 465.36% in Q1 2026.
- On a quarterly basis, EBT Margin changed N/A year-over-year to 465.36% in Q1 2026; TTM through Mar 2026 was 787.47%, a N/A change from a year earlier, with the FY2025 full-year figure at 5617.67%, changed N/A from the prior year.
- EBT Margin for Q1 2026 stood at 465.36%, up from 482.25% in the prior quarter.
- Over the last five years, EBT Margin for NRXP reached as high as 465.36% in Q1 2026 and fell as low as 2105.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 34.77% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 18.99% |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 | -465.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -465.36% |
| Dec 31, 2025 | -482.25% |
| Sep 30, 2025 | -2,105.50% |